VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

Status:	Terminated
Conditions:	Pulmonary
Therapuetic Areas:	Pulmonary / Respiratory Diseases
Healthy:	No
Age Range:	18 - Any
Updated:	3/1/2019
Start Date:	February 20, 2018
End Date:	January 14, 2019

A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients

The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a
novel mechanism of action in immunocompromised adults with invasive aspergillosis.

To compare the safety and efficacy of VL-2397 to standard first-line treatment for invasive
aspergillosis in immunocompromised adults with acute leukemia or recipients of an allogeneic
hematopoietic cell transplant (allo-HCT).

Inclusion Criteria:

- Acute Leukemia (AML or ALL) patient or allo-HCT recipient with a diagnosis of IA

Exclusion Criteria:

- Pregnant or breastfeeding

- IA involving sites other than lungs and sinuses

- Graft failure, acute or extensive chronic GvHD

- Uncontrolled diabetes

We found this trial at

sites

Washington University School of Medicine, Division of Infectious Disease

Saint Louis, Missouri 63110

Phone: 314-747-1922

from

Saint Louis, MO